|
CERUS CORPORATION (CERS) DCF Avaliação
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Cerus Corporation (CERS) Bundle
Projetado para precisão, nossa calculadora DCF (CERS) permite avaliar a avaliação da Cerus Corporation usando dados financeiros atualizados, oferecendo flexibilidade completa para modificar todos os parâmetros-chave para melhorar as projeções.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 91.9 | 130.9 | 162.0 | 156.4 | 180.3 | 215.4 | 257.4 | 307.6 | 367.5 | 439.2 |
| Revenue Growth, % | 0 | 42.36 | 23.83 | -3.51 | 15.29 | 19.49 | 19.49 | 19.49 | 19.49 | 19.49 |
| EBITDA | -51.4 | -46.0 | -34.1 | -26.5 | -14.2 | -59.0 | -70.5 | -84.2 | -100.6 | -120.3 |
| EBITDA, % | -55.89 | -35.14 | -21.03 | -16.97 | -7.89 | -27.38 | -27.38 | -27.38 | -27.38 | -27.38 |
| Depreciation | 4.5 | 4.6 | 4.6 | 2.6 | .0 | 5.5 | 6.6 | 7.9 | 9.4 | 11.3 |
| Depreciation, % | 4.85 | 3.49 | 2.81 | 1.66 | 0 | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 |
| EBIT | -55.8 | -50.6 | -38.6 | -29.1 | -14.2 | -64.5 | -77.1 | -92.1 | -110.1 | -131.5 |
| EBIT, % | -60.73 | -38.63 | -23.84 | -18.63 | -7.89 | -29.95 | -29.95 | -29.95 | -29.95 | -29.95 |
| Total Cash | 133.6 | 129.4 | 102.2 | 65.9 | 80.5 | 150.2 | 179.5 | 214.5 | 256.3 | 306.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 21.2 | 25.1 | 34.4 | 35.5 | 29.8 | 44.2 | 52.9 | 63.2 | 75.5 | 90.2 |
| Account Receivables, % | 23.03 | 19.2 | 21.24 | 22.7 | 16.52 | 20.54 | 20.54 | 20.54 | 20.54 | 20.54 |
| Inventories | 23.3 | 26.8 | 29.0 | 39.9 | 38.2 | 47.5 | 56.8 | 67.9 | 81.1 | 96.9 |
| Inventories, % | 25.3 | 20.47 | 17.9 | 25.5 | 21.16 | 22.07 | 22.07 | 22.07 | 22.07 | 22.07 |
| Accounts Payable | 24.2 | 35.6 | 33.0 | 23.8 | 21.7 | 43.6 | 52.1 | 62.3 | 74.4 | 88.9 |
| Accounts Payable, % | 26.34 | 27.21 | 20.37 | 15.25 | 12.03 | 20.24 | 20.24 | 20.24 | 20.24 | 20.24 |
| Capital Expenditure | -1.6 | -.9 | -2.0 | -4.6 | -2.8 | -3.5 | -4.2 | -5.0 | -6.0 | -7.2 |
| Capital Expenditure, % | -1.76 | -0.6954 | -1.23 | -2.94 | -1.57 | -1.64 | -1.64 | -1.64 | -1.64 | -1.64 |
| Tax Rate, % | -0.7805 | -0.7805 | -0.7805 | -0.7805 | -0.7805 | -0.7805 | -0.7805 | -0.7805 | -0.7805 | -0.7805 |
| EBITAT | -56.1 | -50.9 | -39.1 | -29.3 | -14.3 | -64.5 | -77.1 | -92.1 | -110.1 | -131.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -73.5 | -43.3 | -50.6 | -52.4 | -11.9 | -64.5 | -84.1 | -100.5 | -120.1 | -143.5 |
| WACC, % | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -356.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -146 | |||||||||
| Terminal Value | -1,504 | |||||||||
| Present Terminal Value | -863 | |||||||||
| Enterprise Value | -1,220 | |||||||||
| Net Debt | 13 | |||||||||
| Equity Value | -1,233 | |||||||||
| Diluted Shares Outstanding, MM | 185 | |||||||||
| Equity Value Per Share | -6.68 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real CERS financials.
- Real-World Data: Historical data and forward-looking estimates (as highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effects of your inputs on Cerus Corporation’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Financial Data: Cerus Corporation’s (CERS) historical financial statements and pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Valuation: Instantly view Cerus Corporation’s (CERS) intrinsic value updates as you modify inputs.
- Intuitive Visualizations: Dynamic dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the prebuilt Excel template featuring Cerus Corporation's (CERS) data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view the updated results, including Cerus Corporation's (CERS) intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the outputs.
Why Choose This Calculator for Cerus Corporation (CERS)?
- Accurate Data: Up-to-date Cerus Corporation financials provide dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Ready-to-use calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Streamlined design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Healthcare Professionals: Understand the latest advancements in medical technologies and their market implications.
- Researchers: Utilize data on Cerus Corporation (CERS) for academic studies and clinical research.
- Investors: Evaluate your investment strategies by analyzing the performance and growth potential of Cerus Corporation (CERS).
- Market Analysts: Enhance your analysis with comprehensive data and insights on Cerus Corporation (CERS).
- Biotech Entrepreneurs: Learn from the operational strategies of established companies like Cerus Corporation (CERS).
What the Template Contains
- Pre-Filled Data: Includes Cerus Corporation’s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Cerus Corporation’s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.